Mainz, Germany

Klaus-Jüergen Pees


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Klaus-Jüergen Pees in Cancer Treatment

Introduction

Klaus-Jüergen Pees is a notable inventor based in Mainz, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the use of substituted-triazolopyrimidines as anticancer agents.

Latest Patents

Klaus-Jüergen Pees holds 1 patent for his invention titled "Substituted-triazolopyrimidines as anticancer agents." This patent provides a method for treating or inhibiting the growth of cancerous tumor cells and associated diseases in mammals. The method involves administering an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. Additionally, it describes a process for promoting microtubule polymerization by interacting with tubulin and microtubules.

Career Highlights

Klaus-Jüergen Pees has had a distinguished career, working with Wyeth, a prominent pharmaceutical company. His research has focused on developing effective treatments for cancer, showcasing his commitment to improving patient outcomes through innovative solutions.

Collaborations

Throughout his career, Klaus-Jüergen Pees has collaborated with esteemed colleagues, including Mark R Schmitt and Donald R Kirsch. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Klaus-Jüergen Pees is a pioneering inventor whose work in the field of cancer treatment has the potential to make a significant impact on healthcare. His innovative approach to developing anticancer agents demonstrates the importance of research and collaboration in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…